That was the biotech's first commercialized product, highlighting its expertise in messenger RNA technology. This involves teaching the body to make proteins that will prevent or fight a certain disease. Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand declined later in the crisis, the company's earnings and stock price also suffered. But Moderna took steps to turn things around, including cost cuts, a focus on oncology and rare-disease candidates, and the release of new products.
POLARIS INSIGHTS